Non-insulin Therapies forDiabetes Market: Regional Insights
On the basis of region, theglobal Non-InsulinTherapies for Diabetes Market is segmented into North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa. North America isexpected to drive growth of the non-insulin therapies for diabetes market dueto highest diabetes expenditure in the U.S. According to the InternationalDiabetes Federation (IDF), in 2017, around 17,100 new cases of diabetes weredetected in the U.S. Asia Pacific is one of the most lucrative region due to increaseddiabetes burden in China and India, collectively having over 180 millionpatients suffering from diabetes. According to the American DiabetesAssociation (ADA), rising incidence of type 2 diabetes in South Asia is likelyto be over 150% between 2000 and 2035.
Non-insulin therapies are mostlyused in type 2 diabetes patients, where body either does not produce enoughinsulin or is unable to effectively use the insulin it produces.Non-insulin-based medication works with different mechanism of action to reduceblood glucose level and maintain it for optimum glycemic control. For instance,some agents increase the insulin release from pancreatic cells (Sulfonylureas),some agents increase glucose uptake by periphery and reduces hepatic glucoseoutput (Biguanides), some agents slow down digestion of starch in smallintestine (alpha glucosidase inhibitors), and some medication reduces post mealsugar by blocking certain enzymes (Incretin mimetics).
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2042
Non-Insulin Therapies forDiabetes Market Dynamics
Increasing global incidence andprevalence of diabetes is expected to fuel growth of the non-insulin therapiesfor diabetes market. Non-insulin therapies are mainly used in type 2 diabetes,which accounts for around 90% of the global diabetes cases. According to theInternational Diabetes Federation’s (IDF) Diabetes Atlas 2017, worldwideprevalence of diabetic patients was around 425 million, of which around 400million patients were suffering from type 2 diabetes. As per the World HealthOrganization (WHO) 2017 report, diabetes is one of the top 3 causes of deathamong non-communicable diseases worldwide, with 114.4 million cases in China,72.9 million cases in India, and 30.2 million cases in the U.S.
The global economic burden ofdiabetes is high and is expected to substantially increase over the forecastperiod. According to the American Diabetes Association research in March 2018,the total costs of diagnosed diabetes have risen to US$ 327 billion in 2017from US$ 245 billion in 2012. Therefore, non-insulin therapies for diabetesmarket is expected to witness growth in the near future.
Moreover, companies are launchingnew products and combination therapies in the market, which is expected todrive growth of the global non-insulin therapies for diabetes market. Forinstance, in 2017, the Food and Drug Administration (FDA) approved NovoNordisk’s Ozempic (semiglutide), which is once a week GLP-1 analog, would increasethe patient compliance. In December 2017, FDA approved the sodium-glucoseco-transporter 2 (SGLT2) inhibitor called ertugliflozin (Steglatro), which isjointly developed by the Merck & Co. and Pfizer Inc. and in January 2018,the European Medicines Agency (EMA) granted approval for the same in Europe.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/non-insulin-therapies-for-diabetes-market-2042
However, high cost of newer classof drugs when compared to the conventional drugs are expected to negativelyimpact the non-insulin therapies for diabetes market growth, especially inregions such as South Asia, where there is large number of patients sufferingfrom type 2 diabetes. For instance, GLP-1 analog costs around US$ 492 for 30day therapy, whereas Biguanides and sulfonylureas costs around US$ 5-9 for 30day therapy.
Non-insulin Therapies for DiabetesMarket: Competitive Landscape
Key players operating in theglobal non-insulin therapies for diabetes market include AstraZeneca,Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company,GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck andCompany, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, and TakedaPharmaceuticals.
Major players are increasinglytargeting the newer class of drugs such as GLP-1 analogs or SGLT2. SGLT 2inhibitors have been approved for use, as a treatment for diabetes since 2013.Most of the drugs under SGL2 inhibitors such as Dapagliflozin, Canagliflozin,and Empagliflozin were launched after 2013. However, intense competition in themarket could make it difficult for one particular company to grab larger marketshare in the non-insulin therapies for diabetes market.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2042
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
